Analyst: All of the building blocks for Genmab's upgrade were in place
Novartis, Horizon and Janssen have all reported good results for the drugs from which Genmab receives royalties. It therefore doesn't come as a surprise that the company has chosen to upgrade its financial huidance shortly before the release of its report, says an analyst at Sydbank.
BY MARKETWIRE, TRANSLATED BY DANIEL
Over the past 14 days, news of drug sales surpassing expectations has trickled in from Genmab's partners, who pay royalties from the sales of Genmab-developed drugs. It should therefore come as no surprise that the company upgraded its financial expectations on Thursday night, says Senior Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab upgrades financial guidance again
For subscribers
Horizon's Genmab drug gets blockbuster status
For subscribers
Analyst: Novartis's Kesimpta sales exceeded expectations
For subscribers
